Hookipa Pharma Stock Today
| HOOK Stock | USD 1.25 0.06 5.04% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Hookipa Pharma is selling for 1.25 as of the 19th of March 2025. This is a 5.04 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.18. Hookipa Pharma has about a 30 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of April 2019 | Category Healthcare | Classification Health Care |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company was incorporated in 2011 and is headquartered in New York, New York. The company has 9.66 M outstanding shares of which 84.09 K shares are currently shorted by private and institutional investors with about 1.21 trading days to cover. More on Hookipa Pharma
Moving together with Hookipa Stock
| 0.73 | A | Agilent Technologies | PairCorr |
| 0.85 | ME | 23Andme Holding | PairCorr |
| 0.85 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against Hookipa Stock
Hookipa Stock Highlights
| CEO Director | Malte MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHookipa Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hookipa Pharma's financial leverage. It provides some insight into what part of Hookipa Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hookipa Pharma (HOOK) is traded on NASDAQ Exchange in USA. It is located in 350 Fifth Avenue, New York, NY, United States, 10118 and employs 82 people. Hookipa Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.35 M. Hookipa Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.66 M outstanding shares of which 84.09 K shares are currently shorted by private and institutional investors with about 1.21 trading days to cover.
Hookipa Pharma currently holds about 117.92 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Hookipa Pharma Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Hookipa Pharma is $14.35 Million. Over half of Hookipa Pharma's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Hookipa Ownership Details
Hookipa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-12-31 | 32.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 25.3 K | |
| Engineers Gate Manager Lp | 2024-12-31 | 23.7 K | |
| Royal Bank Of Canada | 2024-12-31 | 19.4 K | |
| State Street Corp | 2024-12-31 | 17 K | |
| Northern Trust Corp | 2024-12-31 | 15.7 K | |
| Millennium Management Llc | 2024-12-31 | 15.3 K | |
| Blackrock Inc | 2024-12-31 | 12.2 K | |
| Boothbay Fund Management, Llc | 2024-12-31 | 11.7 K | |
| Baker Bros Advisors Lp | 2024-12-31 | 812.8 K | |
| Siren, L.l.c. | 2024-12-31 | 566.6 K |
Hookipa Pharma Historical Income Statement
Hookipa Stock Against Markets
Hookipa Pharma Corporate Management
| Lukas Flatz | CoFounder | Profile | |
| Klaus Orlinger | Chief Officer | Profile | |
| Reinhard Kandera | CFO Director | Profile | |
| Matthew Beck | Executive Relations | Profile | |
| Mark Winderlich | Chief Officer | Profile | |
| Joern Aldag | CEO Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.47) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.